Sustainability | January 23, 2025
Strides Pharma debuts with ESG rating of 76/100 in the S&P Global’s CSA 2024
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
With over 28 years of experience in the pharmaceutical industry, he is a seasoned Techno? Commercial professional and accomplished top management leader
Investment will fund expansion to meet rising demand for CRDMO services
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Initiative aimed at enhancing workforce skills and competency in line with industry standards so as to create a talented workforce for the Fourth Industrial Revolution
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
Subscribe To Our Newsletter & Stay Updated
